Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

Hepatology

Volumn 66, Issue 3, 2017, Pages 736-745

  Hézode, Christophe ^a   Colombo, Massimo ^b   Bourlière, Marc ^c   Spengler, Ulrich ^d   Ben Ari, Ziv ^e   Strasser, Simone I ^f   Lee, William M ^g   Morgan, Leslie ^h   Qiu, Jingjun ^h   Hwang, Peggy ^h   Robertson, Michael ^h   Nguyen, Bach Yen ^h   Barr, Eliav ^h   Wahl, Janice ^h   Haber, Barbara ^h   Chase, Robert ^h   Talwani, Rohit ^h   Marco, Vito Di ⁱ  

^a HENRI MONDOR HOSPITAL   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c HÔPITAL SAINT JOSEPH   (France)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ADULT; BLOOD COAGULATION DISORDERS, INHERITED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; FOLLOW UP; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TEST; MALE; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; BENZOFURANS; BIOPSY, NEEDLE; BLOOD COAGULATION DISORDERS, INHERITED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; QUINOXALINES; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85018230276     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29139     Document Type: Article

References (18)

1. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000;47:845-851.
2. Fransen van de Putte DE, Makris M, Fischer K, Lee TT, Kirk L, van Erpecum KJ, et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014;60:39-45.
3. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti, Telfer P, Harmatz P, et al.; on behalf of the Italian Society for the Study of Thalassemia and Haemoglobinopathies and Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010;116:2875-2883.
4. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-954.
5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatobiliary Pancreat Surg 2015;63:199-236.
6. Stedman CAM, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia 2016;22:214-217.
7. Zepatier (elbasvir and grazoprevir) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2016.
8. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56:4161-4167.
9. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 2013;8:1930-1940.
10. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-1086.
11. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-1097.
12. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13.
13. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015;63:564-572.
14. Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis 2016;62:32-36.
15. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:e319-e327.
16. Roth D, Nelson DR, Bruchfeld A, Liapakis AM, Silva M, Monsour H, Jr., et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545.
17. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al.; for the IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593.
18. Zeuzem S, Rockstroh JK, Kwo PY, Roth D, Lawitz E, Sulkowski MS, et al. Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)–infected patients: integrated analysis of phase 2-3 trials. Hepatology 2015;62(1 Suppl):554A-555A. Abstract 700.